Overview: Fluoxetine TestIntroduction: The Fluoxetine Test measures fluoxetine levels to monitor antidepressant treatment, preventing mood swings or side effects. Aligned with 2023 APA guidelines, it uses an immunoassay for high sensitivity, aiding in drug monitoring. This test is critical for guiding dose adjustments and improving outcomes in toxicology for patients with depression.
Other Names: Fluoxetine Assay, Prozac Monitoring Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Fluoxetine testing began in the 1990s with antidepressant research. Immunoassays emerged in the 2000s, improving accuracy for therapeutic drug monitoring.
Purpose: Monitors fluoxetine levels, guides dose adjustments, and prevents side effects in patients with depression.
Test Parameters: 1. Fluoxetine
Pretest Condition: No fasting required. Collect serum or plasma at trough levels (before next dose). Report symptoms like mood swings or side effects, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document depression, mood swings, or side effects. Include current medications, especially antidepressants.
Consent: Written consent required, detailing the tests purpose, monitoring implications, and potential need for dose adjustments.
Procedural Considerations: Uses an immunoassay to measure fluoxetine levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper timing of sample collection or medications can affect results. Hemolysis may degrade samples.
Clinical Significance: Therapeutic fluoxetine levels ensure effective treatment. High or low levels prompt dose adjustments to prevent toxicity or inefficacy.
Specialist Consultation: Consult a psychiatrist for result interpretation.
Additional Supporting Tests: Other antidepressant levels, liver function tests, or psychiatric evaluation to monitor treatment.
Test Limitations: Drug interactions may affect levels. Results require clinical correlation.
References: APA Depression Guidelines, 2023; Journal of Clinical Psychiatry, Hirsch M, 2022.
